Ma, CX, Ma, XN, Liu, JJ, Guan, CH, Li, YD, Zhao, N, Mauricio, D, Fu, SB. The BRAFV600E mutation maintains the aggressiveness of papillary thyroid cancers requiring downregulation of primary cilia. MOLECULAR AND CELLULAR ENDOCRINOLOGY. 2024; 581DOI:10.1016/j.mce.2023.112113. PMID:37989409. IF:3.600(Q2/4D).

Beato-Víbora, PI, Chico, A, Moreno-Fernandez, J, Bellido-Castañeda, V, Nattero-Chávez, L, Picón-César, MJ, Martínez-Brocca, MA, Giménez-Alvarez, M, Aguilera-Hurtado, E, Climent-Biescas, E, Azriel-Mir, S, Rebollo-Román, A, Yoldi-Vergara, C, Pazos-Couselo, M, Alonso-Carril, N, Quirós, C. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. DIABETES CARE. 2024; 47(2)DOI:10.2337/dc23-1355. PMID:37948469. IF:16.600(Q1/1D).

Villanueva, C, Sapena, V, Lo, GH, Seo, YS, Shah, HA, Singh, V, Tripathi, D, Schepke, M, Gheorghe, C, Bonilha, DQ, Jutabha, R, Wang, HM, Rodrigues, SG, Brujats, A, Lee, HA, Azam, Z, Kumar, P, Hayes, PC, Sauerbruch, T, Chen, WC, Iacob, S, Libera, ED, Jensen, DM, Alvarado, E, Torres, F, Bosch, J. Improving primary prophylaxis of variceal bleeding by adapting therapy to the clinical stage of cirrhosis. A competing-risk meta-analysis of individual participant data. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2024; 59(3)DOI:10.1111/apt.17824. PMID:38108646. IF:6.700(Q1/1D).

Torné-Ruiz, A, Reguant, M, Sanromà-Ortiz, M, Piriz, M, Roca, J, García-Expósito, J. Assessment, Treatment, and Follow-Up of Phlebitis Related to Peripheral Venous Catheterisation: A Delphi Study in Spain. Healthcare. 2024; 12(3)DOI:10.3390/healthcare12030378. PMID:38338263. IF:2.700(Q2/4D).

Molina-Collada, J, Alonso, F, Otero, L, Bohórquez, C, Torné, CD, García, CP, Madrigal, JMB, Vela, P, Alvaro-Gracia, JM, Castrejón, I. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2024; 64DOI:10.1016/j.semarthrit.2023.152341. PMID:38128174. IF:4.400(Q1/1D).

López-Medina, C, Calvo-Gutiérrez, J, Abalos-Aguilera, MC, Cepas, F, Plasencia-Rodríguez, C, Martínez-Feito, A, Balsa, A, Faré-García, R, Juan-Mas, A, Ruiz-Esquide, V, Sainz, L, Díaz-Torné, C, Godoy-Navarrete, FJ, Añón-Oñate, I, Mena-Vázquez, N, Manrique-Arija, S, Moreno-García, MS, Ortega-Castro, R, Escudero-Contreras, A. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024; 10(1)DOI:10.1136/rmdopen-2023-003975. PMID:38395455. IF:4.700(Q1/1D).

Castellá, M, Mestres-Arenas, A, Gavaldà-Navarro, A, Blasco-Roset, A, Quesada-López, T, Romero-Carramiñana, I, Giralt, M, Villarroya, F, Cereijo, R. The splicing factor SF3B1 is involved in brown adipocyte thermogenic activation. BIOCHEMICAL PHARMACOLOGY. 2024; 220DOI:10.1016/j.bcp.2023.116014. PMID:38158020. IF:5.600(Q1/1D).

Schreurs, MAC, Cajal, TRY, Adank, MA, Collee, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7.900(Q1/1D).